Innate Pharma
Clinical trials sponsored by Innate Pharma, explained in plain language.
-
New antibody shows promise in slowing Early-Stage bone marrow cancer
Disease control CompletedThis study tested an experimental antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The goal was to see if the drug could shrink or slow the cancer while checking for side effects. Participants received one of two dos…
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New drug shows promise against rare blood cancer
Disease control CompletedThis study tested a drug called IPH4102 in 170 people with advanced T-cell lymphoma, a type of blood cancer. The goal was to see if the drug could shrink tumors and how safe it was. Participants received the drug alone or with chemotherapy. The trial is now complete.
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated May 20, 2026 11:55 UTC